SCHEMBL13974405

SCHEMBL13974405

CN(C)c1ccc(-c2nc3cc(-c4ccc5nc(-c6ccc(N(C)C)cc6)[nH]c5c4)ccc3[nH]2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TCF4 P15884 1/20 0.70
CTNNB1 P35222 1/20 0.70
AURKA O14965 7/20 0.59
SIRT2 Q8IXJ6 1/20 0.56
SIRT1 Q96EB6 1/20 0.56
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MAPT P10636 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
POLB P06746 2/20 0.50
RXFP1 Q9HBX9 2/20 0.50
ALDH1A1 P00352 2/20 0.50
GLA P06280 2/20 0.50
RECQL P46063 2/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
GMNN O75496 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8767834 0.94 TCF4 (0.78) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL13836671 0.94 TCF4 (0.64) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL8770642 0.84 HPSE (0.61) TCF4CTNNB1SIRT2SIRT1MEN1
SCHEMBL8768776 0.84 HPSE (0.61) TCF4CTNNB1SIRT2SIRT1MEN1
SCHEMBL17370980 0.84 TCF4 (0.59) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL22232949 0.84 TCF4 (0.72) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL31005272 0.84 TCF4 (0.59) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL31005274 0.84 TCF4 (0.59) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL1663530 0.82 MEN1 (0.77) TCF4CTNNB1AURKASIRT2SIRT1
SCHEMBL1663529 0.82 TCF4 (0.58) TCF4CTNNB1AURKASIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF TCF4 1183/4885CTNNB1 2581/4885AURKA 2410/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF TCF4 1183/4885CTNNB1 2581/4885AURKA 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.